trending Market Intelligence /marketintelligence/en/news-insights/trending/g72bIGl3kmd7KjHhBKtH9w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck & Co. to develop cancer therapies with Taiho, Otsuka

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Merck & Co. to develop cancer therapies with Taiho, Otsuka

Merck & Co. Inc. agreed to collaborate with Japan's Taiho Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co. Ltd. to develop several cancer therapies, especially ones targeting the KRAS gene mutation.

Kenilworth, N.J.-based Merck said it will pay $50 million up front to receive an exclusive global license to therapies developed as a result of the program, and that it will be responsible for funding the research and development and global commercialization of the said therapies.

Taiho and Otsuka can also net up to a further $2.5 billion if the products meet certain preclinical, clinical, regulatory and sales milestones, and are eligible to receive royalties on the sales of therapies that are commercialized.

Taiho will keep co-commercialization rights for the products in Japan. The Tokyo-based pharmaceutical will also have an option to promote the products in specific areas of South East Asia.

The companies plan to pool together their selected preclinical candidates as well as data from their respective cancer research programs to identify therapies that can be advanced.

KRAS is a type of gene that when mutated, has the potential to cause cancer. KRAS mutations occur in about 90% of pancreatic cancers and 20% of non-small cell lung cancer.